Pasar al contenido principal

ESTIMULACION MECANICA EN CHIP: INTERROGANDO LA SEÑALIZACION DE LAS ACTIVINAS

PID2022-141212OA-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Human iPSCs as model systems for BMP-related rare diseases

  • Sánchez-Duffhues, Gonzalo
  • Hiepen, Christian
This article belongs to the Special Issue iPS Cells (iPSCs) for Modelling and Treatment of Human Diseases 2022., Disturbances in bone morphogenetic protein (BMP) signalling contribute to onset and development of a number of rare genetic diseases, including Fibrodysplasia ossificans progressiva (FOP), Pulmonary arterial hypertension (PAH), and Hereditary haemorrhagic telangiectasia (HHT). After decades of animal research to build a solid foundation in understanding the underlying molecular mechanisms, the progressive implementation of iPSC-based patient-derived models will improve drug development by addressing drug efficacy, specificity, and toxicity in a complex humanized environment. We will review the current state of literature on iPSC-derived model systems in this field, with special emphasis on the access to patient source material and the complications that may come with it. Given the essential role of BMPs during embryonic development and stem cell differentiation, gain- or loss-of-function mutations in the BMP signalling pathway may compromise iPSC generation, maintenance, and differentiation procedures. This review highlights the need for careful optimization of the protocols used. Finally, we will discuss recent developments towards complex in vitro culture models aiming to resemble specific tissue microenvironments with multi-faceted cellular inputs, such as cell mechanics and ECM together with organoids, organ-on-chip, and microfluidic technologies., C.H. was funded by “The Open Access Publication Fund of the Westphalian University of Applied Sciences” as well as the 5th Research Challenge on Sustainability (Internal program for science promotion of a sustainable future by the Westphalian University of Applied Sciences). G.S.-D. is sponsored by Fundació La Marató de TV3 (#202038), the Spanish Ministry of Science, through the Ramón y Cajal grants RYC2021-030866-I and PID2022-141212OA-I00, and the BHF-DZHK-DHF, 2022/23 award PROMETHEUS. Both authors would like to thank the Scientific Research Network by the Research Foundation–Flanders (WOG W0014200N) and An Zwijsen., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Sex-biased TGFβ signalling in pulmonary arterial hypertension

  • Wits, Marius
  • Becher, Clarissa
  • Man, Frances de
  • Sánchez-Duffhues, Gonzalo
  • Goumans, Marie-José
Pulmonary arterial hypertension (PAH) is a rare cardiovascular disorder leading to pulmonary hypertension and, often fatal, right heart failure. Sex differences in PAH are evident, which primarily presents with a female predominance and increased male severity. Disturbed signalling of the transforming growth factor-β (TGFβ) family and gene mutations in the bone morphogenetic protein receptor 2 (BMPR2) are risk factors for PAH development, but how sex-specific cues affect the TGFβ family signalling in PAH remains poorly understood. In this review, we aim to explore the sex bias in PAH by examining sex differences in the TGFβ signalling family through mechanistical and translational evidence. Sex hormones including oestrogens, progestogens, and androgens, can determine the expression of receptors (including BMPR2), ligands, and soluble antagonists within the TGFβ family in a tissue-specific manner. Furthermore, sex-related genetic processes, i.e. Y-chromosome expression and X-chromosome inactivation, can influence the TGFβ signalling family at multiple levels. Given the clinical and mechanistical similarities, we expect that the conclusions arising from this review may apply also to hereditary haemorrhagic telangiectasia (HHT), a rare vascular disorder affecting the TGFβ signalling family pathway. In summary, we anticipate that investigating the TGFβ signalling family in a sex-specific manner will contribute to further understand the underlying processes leading to PAH and likely HHT., Our research is supported by the Dutch Cardiovascular Alliance (Hartstichting, Nederlandse Federatie van Universitair Medische Centra (NFU), Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Koninklijke Nederlandse Akademie van Wetenschappen), PHAEDRA-IMPACT (CVON-2018-29) and DOLPHIN-GENESIS (CVON-2017-10). GSD is also sponsored by Fundació La Marato de TV3 (grant #202038), the Spanish Ministerio de Ciencia e Innovación (“Ramon y Cajal” grant RYC2021-030866-I and PID2022-141212OA-I00). GSD and FdM are supported by the BHF-DZHK-DHF, 2022/23 award PROMETHEUS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PI3Kα inhibition blocks osteochondroprogenitor specification and the hyper-inflammatory response to prevent heterotopic ossification

  • Valer, José Antonio
  • Deber, Alexandre
  • Wits, Marius
  • Pimenta-Lopes, Carolina
  • Goumans, Marie-José
  • Rosa, José Luis
  • Sánchez-Duffhues, Gonzalo
  • Ventura, Francesc
Reviewed Preprint: Published from the originalpreprint after peer reviewand assessment by eLife., Heterotopic ossification (HO) occurs following mechanical trauma and burns, or congenitally in patients suffering from fibrodysplasia ossificans progressiva (FOP). Recently, we demonstrated that inhibitors of phosphatidyl-inositol 3-kinase alpha (PI3Kα) may be a useful therapy for patients undergoing HO. In this study, using the already marketed BYL719/Alpelisib/Piqray drug, we have confirmed further these results, detailed the underlying mechanisms of action, and optimized the timing of the administration of BYL719. We found that BYL719 effectively prevents HO even when administered up to three to seven days after injury. We demonstrate in cell cultures and in a mouse model of HO that the major actions of BYL719 are on-target effects through the inhibition of PI3Kα, without directly affecting ACVR1 or FOP- inducing ACVR1R206H kinase activities. In vivo, we found that a lack of PI3Kα in progenitors at injury sites is sufficient to prevent HO. Moreover, time course assays in HO lesions demonstrate that BYL719 not only blocks osteochondroprogenitor specification, but also reduces the inflammatory response. BYL719 inhibits the migration, proliferation and expression of pro-inflammatory cytokines in monocytes and mast cells, suggesting that BYL719 hampers the hyper-inflammatory status of HO lesions. Altogether, these results highlight the potential of PI3Kα inhibition as a safe and effective therapeutic strategy for HO., We acknowledge the support fromPromega R&D. Alexandre Deber is a recipient of a F.P.I. fellowship from the Ministry of Scienceand Innovation (MCIN/AEI/ 10.13039/501100011033). Carolina Pimenta-Lopes is the recipient of aF.P.U. fellowship from the Spanish Ministry of Education. This research was supported by grantsPID2022-141212OA-I00, PDC2021-121776-I00 and PID2020-117278GB-I00 fromMCIN/AEI/10.13039/501100011033, co-funded by FEDER ‘Una manera de hacer Europa’ or‘NextGenerationEU’/PRTR; a grant 202038-30 from La Marató de TV3 and grants from IFOPA (ACTfor FOP) and FOPItalia. MW and MJG are sponsored by the Netherlands Cardiovascular ResearchInitiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, theNetherlands Organization for Health Research and Development, and the Royal NetherlandsAcademy of Sciences), PHAEDRA-IMPACT (DCVA) and DOLPHIN-GENESIS (CVON). GSD is alsosponsored by the Spanish Ministry of Science through the Ramón y Cajal grant RYC2021-030866-Iand the BHF-DZHK-DHF, 2022/23 award PROMETHEUS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TGF-β receptor-specific NanoBRET target engagement in living cells for high-throughput kinase inhibitor screens

  • Wits, Marius
  • Haarmans, Nicole
  • Sánchez-Duffhues, Gonzalo
  • Goumans, Marie-José
Targeting transforming growth factor-β (TGF-β) receptors is a promising pharmacological approach to normalize aberrant signaling in genetic and non-genetic TGF-β associated diseases including fibrosis, cancer, cardiovascular and musculoskeletal disorders. To identify novel TGF-β receptor kinase inhibitors, methods like in vitro kinase assays, western blot or transcriptional reporter assays are often used for screening purposes. While these methods may have certain advantages, the lack of integration of key features such as receptor specificity, high-throughput capability, and cellular context resemblance remains a major disadvantage. This deficiency could ultimately hinder the translation of study outcomes into later (clinical) stages of drug development. In this study, we introduce an adjusted and optimized live cell NanoBRET Target Engagement (TE)-based method to identify TGF-β receptor specific kinase inhibitors. This comprehensive toolkit contains various TGF-β type I and type II receptors, with corresponding nanoBRET tracers, and disease-related cell lines, including novel non-commercially available materials. The nanoBRET capacity and kinase inhibitory window can be significantly enhanced for functional measurements when stable expression cell lines and substantially low tracer concentrations are used. In addition, this system can be tailored to study TGF-β associated genetic disorders and possibly be used to screen for disease-specific therapeutics. Therefore, the use of this optimized, live cell, antibody-independent nanoBRET Target Engagement assay is highly encouraged for future high-throughput compound screens targeting TGF-β/BMP receptors., We acknowledge the support from Promega R&D. Galapagos NV provided funding for the conduct of the study and the compounds A-D. Some figures were made using Biorender.com. This research was further supported by grants Ramón y Cajal RYC2021-030866-I, PID2022-141212OA-I00 and CNS2023-145432 from the Spanish Ministry of Science and Innovation (to GSD). GSD is also sponsored by La Marató de TV3 (202038-30), the BHF-DZHK-DHF, 2022/23 award PROMETHEUS (02-001-2022-0123), the Foundation Eugenio Rodriguez Pascual (FERP-2023-058) and the Foundation “Por dos pulgares de nada”. MW and MJG are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences), PHAEDRA-IMPACT (DCVA) and DOLPHIN-GENESIS (CVON). Finally, we thank the Scientific Research Network by the Research Foundation–Flanders (WOG W0014200N) and An Zwijsen., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting soluble TGF-β factors: Advances in precision therapy for pulmonary arterial hypertension

  • Becher, Clarissa
  • Wits, Marius
  • Man, Frances de
  • Sánchez-Duffhues, Gonzalo
  • Goumans, Marie-José
Pulmonary arterial hypertension (PAH) is a rare progressive disease characterized by pulmonary artery vascular remodeling, increased vascular resistance, and subsequent right ventricular hypertrophy and right heart failure. It is triggered by disrupted transforming growth factor (TGF)-β signaling, including loss-of-function mutations in the bone morphogenetic protein (BMP) receptor 2. Emerging treatments aim to inhibit elevated TGF-β levels or enhance diminished endothelial BMP signaling. This review aims to summarize the role of the TGF-β superfamily in the pathobiology of PAH and recent discoveries highlighting altered expression of TGF-β-related soluble factors in PAH patients that can serve as potential biomarkers and drug targets. The discussion focuses on how these altered factors can guide treatment decisions and monitor therapeutic responses, facilitating personalized patient care through the integration of diagnostics and therapy, that is, precision medicine. This approach tailors treatment strategies to individual patients based on their unique disease characteristics., This work was supported by the Dutch Cardiovascular Alliance (PHAEDRA-IMPACT and DOLPHIN-GENESIS). C. Becher is sponsored by the European Joint Programme on Rare Diseases and The Company of Biologists. Dr Sanchez-Duffhues is sponsored by Fundació la Marato de TV3 (grant 202038), the Spanish Ministerio de Ciencia e Innovación (“Ramon y Cajal” RYC2021-030866-I and PID2022-141212OA-I00 grants). Dr Sanchez-Duffhues and Prof de Man are supported by the BHF-DZHK-DHF 2022/23 award PROMETHEUS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

TGFβ signalling: a nexus between inflammation, placental health and preeclampsia throughout pregnancy

  • Horvat Mercnik, Monika
  • Schliefsteiner, Carolin
  • Sánchez-Duffhues, Gonzalo
  • Wadsack, Christian
[Background]: The placenta is a unique and pivotal organ in reproduction, controlling crucial growth and cell differentiation processes that ensure a successful pregnancy. Placental development is a tightly regulated and dynamic process, in which the transforming growth factor beta (TGFβ) superfamily plays a central role. This family of pleiotropic growth factors is heavily involved in regulating various aspects of reproductive biology, particularly in trophoblast differentiation during the first trimester of pregnancy. TGFβ signalling precisely regulates trophoblast invasion and the cell transition from cytotrophoblasts to extravillous trophoblasts, which is an epithelial-to-mesenchymal transition-like process. Later in pregnancy, TGFβ signalling ensures proper vascularization and angiogenesis in placental endothelial cells. Beyond its role in trophoblasts and endothelial cells, TGFβ signalling contributes to the polarization and function of placental and decidual macrophages by promoting maternal tolerance of the semi-allogeneic foetus. Disturbances in early placental development have been associated with several pregnancy complications, including preeclampsia (PE) which is one of the severe complications. Emerging evidence suggests that TGFβ is involved in the pathogenesis of PE, thereby offering a potential target for intervention in the human placenta., [Objective and rationale]: This comprehensive review aims to explore and elucidate the roles of the major members of the TGFβ superfamily, including TGFβs, bone morphogenetic proteins (BMPs), activins, inhibins, nodals, and growth differentiation factors (GDFs), in the context of placental development and function. The review focusses on their interactions within the major cell types of the placenta, namely trophoblasts, endothelial cells, and immune cells, in both normal pregnancies and pregnancies complicated by PE throughout pregnancy., [Search methods]: A literature search was carried out using PubMed and Google Scholar, searching terms: 'TGF signalling preeclampsia', 'pregnancy TGF signalling', 'preeclampsia tgfβ', 'preeclampsia bmp', 'preeclampsia gdf', 'preeclampsia activin', 'endoglin preeclampsia', 'endoglin pregnancy', 'tgfβ signalling pregnancy', 'bmp signalling pregnancy', 'gdf signalling pregnancy', 'activin signalling pregnancy', 'Hofbauer cell tgfβ signalling', 'placental macrophages tgfβ', 'endothelial cells tgfβ', 'endothelium tgfβ signalling', 'trophoblast invasion tgfβ signalling', 'trophoblast invasion Smad', 'trophoblast invasion bmp', 'trophoblast invasion tgfβ', 'tgfβ preeclampsia', 'tgfβ placental development', 'TGFβ placental function', 'endothelial dysfunction preeclampsia tgfβ signalling', 'vascular remodelling placenta TGFβ', 'inflammation pregnancy tgfβ', 'immune response pregnancy tgfβ', 'immune tolerance pregnancy tgfβ', 'TGFβ pregnancy NK cells', 'bmp pregnancy NK cells', 'bmp pregnancy tregs', 'tgfβ pregnancy tregs', 'TGFβ placenta NK cells', 'TGFβ placenta tregs', 'NK cells preeclampsia', 'Tregs preeclampsia'. Only articles published in English until 2023 were used., [Outcomes]: A comprehensive understanding of TGFβ signalling and its role in regulating interconnected cell functions of the main placental cell types provides valuable insights into the processes essential for successful placental development and growth of the foetus during pregnancy. By orchestrating trophoblast invasion, vascularization, immune tolerance, and tissue remodelling, TGFβ ligands contribute to the proper functioning of a healthy maternal-foetal interface. However, dysregulation of TGFβ signalling has been implicated in the pathogenesis of PE, where the shallow trophoblast invasion, defective vascular remodelling, decreased uteroplacental perfusion, and endothelial cell and immune dysfunction observed in PE, are all affected by an altered TGFβ signalling., [Wider implications]: The dysregulation of TGFβ signalling in PE has important implications for research and clinical practice. Further investigation is required to understand the underlying mechanisms, including the role of different ligands and their regulation under pathophysiological conditions, in order to discover new therapeutic targets. Distinguishing between clinically manifested subtypes of PE and studying TGFβ signalling in different placental cell types holistically is an important first step. To put this knowledge into practice, pre-clinical animal models combined with new technologies are needed. This may also lead to improved human research models and identify potential therapeutic targets, ultimately improving outcomes for affected pregnancies and reducing the burden of PE., M.H.M. is supported through the PhD Program Inflammatory Disorders in Pregnancy (DP-iDP) by the Austrian Science Fund FWF (Doc 31-B26) and the Medical University of Graz, Austria. C.S. holds a post-doctoral fellowship granted by the Austrian Science Fund FWF (T1029-B26). G.S.-D. is sponsored by Fundació La Marató de TV3 (202038), the BHF-DZHK-DHF, 2022/23 Award PROMETHEUS, and the Spanish Ministry of Science and Innovation through the Ramón y Cajal (RYC2021-030866-I) and the project PID2022-141212OA-I00., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A cost-effective vessel-on-a-chip for high shear stress applications in vascular biology

  • Becher, Clarissa
  • Frauenlob, Martin
  • Selinger, Florian
  • Ertl, Peter
  • Goumans, Marie-José
  • Sánchez-Duffhues, Gonzalo
The data supporting the findings of this study can be obtained from the corresponding authors upon reasonable request., The vascular endothelium is constantly subjected to hemodynamic forces, including tangential shear stress, which are crucial for maintaining vascular homeostasis. Pathological shear stress levels, such as those observed in pulmonary arterial hypertension (PAH) or atherosclerosis, disrupt this balance, driving vascular remodeling and endothelial dysfunction. Current microfluidic platforms for studying these conditions are limited by high costs, excessive reagent requirements, and non-physiological channel geometries. Here we introduce a novel microfluidic chip system, a Nylon Vessel-on-a-Chip (NVoC) which represents a cost-effective and straightforward fabrication platform that eliminates the need for specialized equipment and enables a physiologically relevant round channel geometry. The NVoC was fabricated using Polydimethylsiloxane (PDMS) and nylon threads, with surface activation achieved through polydopamine and collagen-I coating, enabling robust endothelial cell (EC) attachment and long-term culture. Immortalized endothelial colony-forming cells (iECFCs) and human umbilical vein EC (HUVECs) were used to optimize and validate the platform, demonstrating its compatibility with high shear stress conditions (up to 90 dyne/cm2) and various molecular biology techniques, including RT-qPCR, Western blotting, and immunofluorescent staining. With fabrication costs six times lower than commercial alternatives and overall experimental costs reduced threefold, the NVoC offers the ability to expose endothelial cells to physiological and pathological shear stress levels in a reproducible, accessible, and scalable manner. Its versatility and affordability make it a valuable tool for investigating shear stress-related mechanisms in microvascular diseases, particularly PAH, with potential applications in drug discovery and translational research., This research was further supported by the FWO Scientific Research Network (W0014200N). C.B. and M.J.G. are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences), PHAEDRA-IMPACT (DCVA), and DOLPHIN-GENESIS (CVON). C.B was sponsored by the European Union’s Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N° 825575. M.J.G. is supported by regenerative medicine crossing borders (REGMED XB). G.S.D. is supported by the grants Ramón y Cajal RYC2021-030886-I, PID2022-141212OA-I00, and CNS2023-145432 from the Spanish Ministry of Science and Innovation, the BHF-DZHK-DHF, 2022/23 award PROMETHEUS (02-001-2022-0123), and the Foundations Eugenio Rodriguez Pascual (FERP-2023-058) and Mutua Madrileña. F.S. was supported by the Austrian Science Fund (FWF) [doi.org/10.55776/COE7]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interplay between ALK2R206H mutant receptor and autophagy signaling regulates receptor stability and its chondrogenic functions

  • Coculo, Laura
  • Wits, Marius
  • Mariani, Irene
  • Fianco, Giulia
  • Cappato, Serena
  • Bocciardi, Renata
  • Pedemonte, Nicoletta
  • Volpe, Elisabetta
  • Ciolfi, Serena
  • Sessa, Rosario Luigi
  • Rinaldo, Serena
  • Cutruzzolà, Francesca
  • Trisciuoglio, Daniela
  • Goumans, Marie-José
  • Sánchez-Duffhues, Gonzalo
  • Stagni, Venturina
Heterozygous mutations in the Bone morphogenetic protein (BMP) type I receptor ACVR1, encoding activin-like kinase 2 (ALK2), underlie all cases of the rare genetic musculoskeletal disorder Fibrodysplasia Ossificans Progressiva (FOP). The most commonly found mutant ALK2 p.R206H receptor variant exhibits loss of auto inhibition of BMP signaling and can be activated by Activins, while wild-type receptors remain unresponsive. Consequently, the downstream chondrogenic signaling is enhanced, thus driving heterotopic ossification within soft connective tissues. Despite several investigational treatments being evaluated in clinical trials, no cure for FOP exists today. The cellular and molecular mechanisms underlying disease progression are still being deciphered. In this study, we show a close interplay between the mutant ALK2R206H receptor signaling and dysregulation of the autophagic flux triggered by hypoxia. Mechanistically, reduced autophagic flux correlates with increased stability of ALK2R206H, resulting in sustained signaling. Of note, we demonstrated that Rapamycin, under clinical investigation as a treatment for FOP, inhibits chondrogenic differentiation in an autophagy-dependent manner. Consistently, other pharmacological autophagy inducers, like Spermidine, can reduce ALK2R206H driven chondrogenic differentiation in vitro. These results were verified in FOP patient-derived cells. In conclusion, this study shows that aberrant autophagic flux mediates sustained ALK2R206H signaling, introducing a novel druggable target in FOP by reactivating autophagy., We acknowledge the MUR-PON program “IMPARA - Imaging from molecules to preclinical studies” for supporting the implementation of the microscopy infrastructure at IBPM CNR and HypACB infrastructure Sapienza. This research was supported by grants Telethon Seed Grant FOP GSA21A002, Telethon Seed Grant FOP-Renewal GSA23I001, National Recovery and Resilience Plan (NRRP), Mission 4, Component 2, Investment 1.1, Call No. 104 (2.2.2022) by the Italian Ministry of University and Research (MUR), funded by the European Union – NextGenerationEU – PRIN Project N. CUP B53D23015820006 (PRIN202224M22R, to V.S. and L.C.) CUP N. B53D23015930006 (to F.C.), Project N. CUP N. B53D23016330006 (to S.R.), by Short Term Mobility (STM) fellowship (CNR,2022,0039768/2022) for VS, by Ramón y Cajal RYC2021-030866-I, PID2022-141212OA-I00 and CNS2023-145432 from the Spanish Ministry of Science and Innovation for GSD.GSD is also sponsored by the foundations La Marató de TV3 (202038-30), Eugenio Rodriguez Pascual (FERP-2023-058) Foundation “Por dos pulgares de nada” and Mutua Madrileña. MW and MJG are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Sciences), PHAEDRA-IMPACT (DCVA), and DOLPHIN-GENESIS (CVON). Work partially supported by CNR (project DBA.AD005.225-NUTRAGE-FOE2021) and PNRR PE8 Age-IT., co-funding from Next Generation EU [DM 1557 11.10.2022], in the context of the NRRP, Investment PE8—Project Age-It (V.S, D.T., and G.F.) and AIRC grant IG2019 no. 23125 (to F.C.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Accessible and fast single-cell proteomics by DIA integrating Tecan UNO cell dispensing platform, Vanquish Neo LC and Exploris 480 MS

  • Suárez-Fernández, Amanda
  • Bestilleiro-Márquez, Judit
  • Sánchez-Duffhues, Gonzalo
  • Ortea, Ignacio
This article is a preprint and has not been certified by peer review., Recent technological advancements in high-sensitivity LC-MS platforms and MS acquisition strategies have addressed key analytical challenges in single-cell proteomics (SCP), paving the way for SCP to become a transformative tool in biology and medicine. Techniques such as MS2 DIA and HRMS1 DIA exploit wide isolation windows and high-resolution MS1 and MS2 spectra to maximize protein identifications, even from low-abundance signals. In parallel, improved data processing algorithms reduce missing values and enhance the reliability of SCP data. These advancements are complemented by automated cell isolation technologies, which ensure precise single-cell handling with minimal sample loss, and in some implementations enable integrated, automated downstream sample preparation steps. Despite this progress, practical, end-to-end best practices for MS-based SCP remain an active area of optimization. Severe sample limitation, adsorption-related losses, the need for robust quantification across hundreds to thousands of single cells, and the lack of comprehensive protocols that systematically integrate and compare critical workflow variables complicate method selection and SCP implementation. In this context, this study builds on recent LC-MS based SCP advancements by presenting a complete, optimized, minimum user operation SCP workflow that integrates the Tecan UNO cell dispensing platform, a Vanquish Neo LC system, and an Orbitrap Exploris 480 mass spectrometer, applied to human primary cells. The workflow is designed to minimize data/cell loss, ensure high reproducibility, and maximize identifications. We evaluate key parameters, including acquisition schemes and LC gradient and column, and distill practical recommendations. The resulting protocol provides a foundation for an easy and accessible routine SCP application in biology and medicine., IO and GSD are supported by a grant of the Foundation Mutua Madrileña 2024. GSD is also sponsored by the Spanish Ministry of Science and Innovation grants (Ramón y Cajal RYC2021-030866-I, PID2022-141212OA-I00) and the Foundation Eugenio Rodriguez Pascual (FERP-2023-058). ISPA Proteomics Unit has been funded by the Instituto de Salud Carlos III (ISCIII) (project IFCS22/00006) within the framework of the Mechanism for Recovery and Resilience (MRR) of the Next Generation EU funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

BMP9 modulates IL-33 signaling to mitigate EndMT in pulmonary arterial hypertension

  • Becher, Clarissa
  • Groeneveld, Esmee J.
  • Quarck, Rozenn
  • Neep, Beau
  • Pan, Xiaoke
  • Szulcek, Robert
  • Tu, Ly
  • Guignabert, Christophe
  • Bogaard, Harm Jan
  • Yu, Paul B.
  • Man, Frances de
  • Sánchez-Duffhues, Gonzalo
  • Goumans, Marie-José
[Background] Pulmonary arterial hypertension (PAH) is a progressive disorder involving disrupted BMP (bone morphogenetic protein) signaling, pulmonary inflammation, and endothelial-to-mesenchymal transition (EndMT). We hypothesized that IL (interleukin)-33 signaling contributes to PAH progression by inducing EndMT and interacting with BMP9, a key modulator of inflammation and vascular remodeling., [Methods] IL-33 expression was assessed in lung tissues from Sugen/hypoxia and control mice, as well as in pulmonary arterial endothelial cells (PAECs) and lung tissues from patients with PAH and healthy donors. EndMT and signaling pathways were analyzed in PAECs and microvascular endothelial cells (MVECs) exposed to IL-33, BMP9, and sST2 (soluble supression of tumorigenicity 2) using quantitative polymerase chain reaction, Western blotting, ELISA, and immunostaining. Plasma BMP9 and sST2 levels were quantified in patients with PAH., [Results] Immunofluorescent analysis revealed elevated IL-33 expression in pulmonary endothelial cells of Sugen/hypoxia mice compared with controls, consistent with findings in PAECs from patients with PAH. BMP9 significantly upregulated sST2 expression in human PAEC and microvascular endothelial cells, inhibited IL-33 target gene expression, and effectively suppressed IL-33-induced EndMT. Notably, BMP9 demonstrated greater efficacy in preventing EndMT compared with rsST2 (recombinant soluble ST2) or ST2L-neutralizing antibodies. Circulating BMP9 and sST2 levels in the plasma of patients with PAH were positively correlated in specific patient groups stratified by sex, age, and New York Heart Association functional class, suggesting a protective role of BMP9 in modulating IL-33-induced EndMT., [Conclusions] BMP9 plays a protective role against IL-33-induced EndMT in PAECs by upregulating sST2 expression and neutralizing IL-33, suggesting that targeting the IL-33 signaling pathway may represent a promising therapeutic strategy to mitigate EndMT in PAH., This work was supported by the FWO Scientific Research Network (grant W0014200N). C. Becher and M.J. Goumans are sponsored by the Netherlands Cardiovascular Research Initiative (the Dutch Heart Foundation, the Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Arts and Sciences), PHAEDRA-IMPACT (Dutch Cardiovascular Alliance, DCVA), and DOLPHIN-GENESIS (CardioVasculair Onderzoek Nederland, CVON). C. Becher is sponsored by the European Joint Program on Rare Diseases and the Company of Biologists. M.J. Goumans is supported by Regenerative Medicine Crossing Borders. G. Sanchez-Duffhues is supported by the grants Ramón y Cajal RYC2021-030866-I, PID2022-141212OA-I00, and CNS2023-145432 from the Spanish Ministry of Science and Innovation, the British Heart Foundation (BHF)-German Centre for Cardiovascular Research (DZHK)-Dutch Heart Foundation (DHF), 2022/23 award PROMETHEUS (grant 02-001-2022-0123), and the Foundation Eugenio Rodriguez Pascual (grant FERP-2023-058). T, Peer reviewed